These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10465180)

  • 41. Visual field constriction in children with epilepsy on vigabatrin treatment.
    Iannetti P; Spalice A; Perla FM; Conicella E; Raucci U; Bizzarri B
    Pediatrics; 2000 Oct; 106(4):838-42. PubMed ID: 11015531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of vigabatrin on partial seizures and cognitive function.
    Grünewald RA; Thompson PJ; Corcoran R; Corden Z; Jackson GD; Duncan JS
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1057-63. PubMed ID: 8089668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
    Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
    Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vigabatrin-associated retinal cone system dysfunction.
    Beck RW
    Neurology; 1998 Dec; 51(6):1778-9; author reply 1779-81. PubMed ID: 9855562
    [No Abstract]   [Full Text] [Related]  

  • 45. Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients.
    Harding GF
    BMJ; 1998 Jan; 316(7126):232-3. PubMed ID: 9468716
    [No Abstract]   [Full Text] [Related]  

  • 46. In utero exposure to vigabatrin: no indication of visual field loss.
    Lawthom C; Smith PE; Wild JM
    Epilepsia; 2009 Feb; 50(2):318-21. PubMed ID: 18616557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term efficacy and cognitive effects of vigabatrin.
    Ylinen A; Kälviäinen R; Riekkinen PJ
    Acta Neurol Scand Suppl; 1995; 162():47-50. PubMed ID: 7495191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of association between vigabatrin and impaired cognition.
    Monaco F; Torta R; Cicolin A; Borio R; Varetto A; Bergamasco L; Vighetti S
    J Int Med Res; 1997; 25(5):296-301. PubMed ID: 9364292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy.
    Tseng YL; Lan MY; Lai SL; Huang FC; Tsai JJ
    Acta Neurol Taiwan; 2006 Dec; 15(4):244-50. PubMed ID: 17214087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?
    Sorri I; Brigell MG; Mályusz M; Mahlamäki E; de Meynard C; Kälviäinen R
    Epilepsy Res; 2010 Nov; 92(1):48-53. PubMed ID: 20850272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fatal hepatotoxicity in a child treated with vigabatrin.
    Kellermann K; Soditt V; Rambeck B; Klinge O
    Acta Neurol Scand; 1996 May; 93(5):380-1. PubMed ID: 8800351
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products.
    Elferink AJ; Toivonen M; van Bronswijk H
    Lancet; 1999 Oct; 354(9187):1387-8. PubMed ID: 10533890
    [No Abstract]   [Full Text] [Related]  

  • 53. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.
    Krauss GL; Johnson MA; Miller NR
    Neurology; 1998 Mar; 50(3):614-8. PubMed ID: 9521245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The new antiepileptic drugs.
    Macleod S; Appleton RE
    Arch Dis Child Educ Pract Ed; 2007 Dec; 92(6):182-8. PubMed ID: 18032714
    [No Abstract]   [Full Text] [Related]  

  • 55. Recovery of visual field constriction following discontinuation of vigabatrin.
    Krakow K; Polizzi G; Riordan-Eva P; Holder G; MacLeod WN; Fish DR
    Seizure; 2000 Jun; 9(4):287-90. PubMed ID: 10880291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vigabatrin and complex partial status.
    Arzimanoglou A
    Seizure; 1994 Mar; 3(1):79-80. PubMed ID: 8044458
    [No Abstract]   [Full Text] [Related]  

  • 58. The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood.
    McDonald DG; Najam Y; Keegan MB; Whooley M; Madden D; McMenamin JB
    Seizure; 2005 Mar; 14(2):112-6. PubMed ID: 15694564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Visual fields at school-age in children treated with vigabatrin in infancy.
    Gaily E; Jonsson H; Lappi M
    Epilepsia; 2009 Feb; 50(2):206-16. PubMed ID: 19215279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
    Hisama FM; Mattson RH; Lee HH; Felice K; Petroff OA
    Seizure; 2001 Oct; 10(7):505-7. PubMed ID: 11749107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.